RPRD1B Antibody (08) [PerCP]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-06521PCP
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
Immunohistochemistry-Paraffin
Label
PerCP (Excitation = 490 nm, Emission = 675 nm)
Antibody Source
Monoclonal Mouse IgG2B Clone # 08
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human RPRD1B (Accession#: AAH33629.1; Met1-Asp326).
Clonality
Monoclonal
Host
Mouse
Isotype
IgG2B
Applications for RPRD1B Antibody (08) [PerCP]
Application
Recommended Usage
Immunohistochemistry-Paraffin
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
PBS
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: RPRD1B
Alternate Names
Cell cycle-related and expression-elevated protein in tumor, cell-cycle related and expression-elevated protein in tumor, chromosome 20 open reading frame 77, CREPTC20orf77, dJ1057B20.2, DKFZp434P0735, FLJ44520, NET60, regulation of nuclear pre-mRNA domain containing 1B, regulation of nuclear pre-mRNA domain-containing protein 1B
Gene Symbol
RPRD1B
Additional RPRD1B Products
Product Documents for RPRD1B Antibody (08) [PerCP]
Product Specific Notices for RPRD1B Antibody (08) [PerCP]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...